PMC9162556_01
Radiological examinations during the treatment course. (A) PET/CT scan before treatment (23 June 2020). (B) A computer tomography scan after treatment with crizotinib for 6 weeks (21 August 2020). (C) A computer tomography scan after treatment with crizotinib from 17 September 2020 to 28 October 2021.
fonc-12-841493-g001.jpg
PMC9162556_01_fonc-12-841493-g001.jpg
f1
Positron emission tomography/computed tomography (PET/CT) showed a hypermetabolic mass in the middle lobe of the right lung with metastases of hilar and mediastinal lymph nodes, right supraclavicular lymph nodes, and right ilium (T1cN3M1c, stage IVB,  Figure 1A ). After 6 weeks, the CT scan demonstrated reduced tumor size and smaller subcarinal lymph nodes (17 x 12 x 12 mm) compared with the previous examination, and evaluation of therapeutic efficiency indicated partial response (PR, -34.2%) ( Figure 1B ). Figure 1C ). Follow-up CT scans showed SD (0%) and sizes of subcarinal lymph nodes were almost unchanged until October 2021 ( Figure 1C ).
ALK fusion was detected using NGS. (A) Schematic representation of LMO7-ALK (L15, A20). (B) LMO7-ALK (L15, A20) fusion demonstrated by Integrative Genomics Viewed program.
fonc-12-841493-g002.jpg
PMC9162556_01_fonc-12-841493-g002.jpg
f2
The breakpoints of the two genes were chromosome 2 (29446313-29446354) and LMO7 chromosome 13 (76407282-76407322;  Figures 2A, B ).